A 'sur­pris­ing' Phase III knocks back As­traZeneca, Am­gen's block­buster asth­ma am­bi­tions

Two months have brought two very dif­fer­ent re­sults for Am­gen, As­traZeneca and their block­buster-po­ten­tial asth­ma drug.

The com­pa­nies an­nounced Tues­day that the drug — a once …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.